CAZZANIGA MARINA ELENA

Ardakani, K., Passarella, G., Lania, A., Clementi, T., Fanti, A., Pepe, F., et al. (2026). Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review. CURRENT ONCOLOGY, 33(1) [10.3390/curroncol33010028]. Dettaglio

Cazzaniga, M., Cogliati, V., Rossi, E., Paris, I., Borella, F., Moretti, G., et al. (2026). Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study. ESMO REAL WORLD DATA AND DIGITAL ONCOLOGY, 11(March 2026) [10.1016/j.esmorw.2025.100665]. Dettaglio

Garrigos, L., Ruiz-Borrego, M., Perez-Garcia, J., Guerrero-Zotano, A., Cortes-Salgado, A., Kuemmel, S., et al. (2026). A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study☆. ANNALS OF ONCOLOGY, 37(6), 837-848 [10.1016/j.annonc.2026.01.013]. Dettaglio

Hurvitz, S., Layman, R., Curigliano, G., André, F., Cristofanilli, M., Kim, S., et al. (2026). VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer. JOURNAL OF CLINICAL ONCOLOGY, 44(12), 1108-1119 [10.1200/JCO-25-02643]. Dettaglio

Bianchini, G., Malorni, L., Caputo, R., Zambelli, A., Puglisi, F., Bianchi, G., et al. (2026). Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial. CLINICAL CANCER RESEARCH, 32(12), 2428-2437 [10.1158/1078-0432.CCR-25-0650]. Dettaglio